BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried?

Published September 18, 2026 · Category: Finance

Overview

BioNTech's (NASDAQ: BNTX) shares were flying high in the aftermath of Moderna's (NASDAQ: MRNA) and Merck's (NYSE: MRK) announcement of impressive late-stage results for personalized messenger RNA (mRNA) cancer vaccine intismeran autogene in combination with Keytruda. The surge made sense, considering that BioNTech is developing its own mRNA cancer vaccines.

However, BioNTech's momentum came to a screeching halt with the company's update on Aug. 28, 2026, from a Phase 2 study of mRNA vaccine autogene cevumeran in treating colorectal cancer. BioNTech and its partner, Roche's (OTC: RHHBY) Genentech unit, decided to cancel the clinical trial due to a lack of efficacy. Should this move to throw in the towel worry investors?

Image source: Getty Images.

Details

Continue reading

Source

Originally published at www.fool.com.

Related Articles

• I’m in my 50s. My mother died from Alzheimer’s. Do I need long-term insurance?
• Warren Buffett's Successor, Greg Abel, Is Wagering Heavily on an AI-Driven Future
• Can Dogecoin Reach $1 by Year-End? Here's How the Meme Coin Traded During the Last Election Year.